Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.64−0.27 (-2.27%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Mesoblast net income
Net income is the profit left for shareholders after every expense, interest and tax.
Mesoblast's net income for the twelve months ending Jun 30, 2023 was -$81.89M. For fiscal 2026 it was -$57.50M. The highest annual figure on record is -$4.13M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$57.50M | – |
| FY2025 | Jun 30, 2025 | -$102.14M | – |
| FY2024 | Jun 30, 2024 | -$87.96M | – |
| FY2023 | Jun 30, 2023 | -$81.89M | – |
| FY2022 | Jun 30, 2022 | -$91.35M | – |
| FY2021 | Jun 30, 2021 | -$98.81M | – |
| FY2020 | Jun 30, 2020 | -$77.94M | – |
| FY2019 | Jun 30, 2019 | -$89.80M | – |
| FY2018 | Jun 30, 2018 | -$35.29M | – |
| FY2017 | Jun 30, 2017 | -$76.82M | – |
| FY2016 | Jun 30, 2016 | -$4.13M | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$21.92M | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$18.60M | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$24.49M | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$16.88M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$21.46M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$21.30M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$25.95M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$22.65M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$22.06M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$26.52M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$25.69M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$24.54M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$32.61M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$15.26M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$24.58M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$5.48M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$20.73M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$24.97M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$24.60M | -279.6% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$19.50M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$20.83M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$21.14M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $13.70M | – |
See a number that looks wrong?